PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of Olaparib to Platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients
Authors
Drewett, L.Pinilla, K. A.
Grybowicz, L.
Wulff, J.
Dayimu, A.
Demiris, N.
Lucey, R.
Vallier, A. L.
Qian, W. D.
Machin, A.
McAdam, K.
Roylance, R.
Copson, E. R.
Armstrong, Anne C
Levitt, N.
Provenzano, E.
Tischkowitz, M.
McMurtry, E.
Earl, H.
Abraham, J. E.
Affiliation
University of Cambridge and Cambridge University Hospitals NHS Foundation Trust, CambridgeIssue Date
2022
Metadata
Show full item recordCitation
Drewett L, Pinilla KA, Grybowicz L, Wulff J, Dayimu A, Demiris N, et al. Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC. Cancer Research. 2022 Jun;82(12). PubMed PMID: WOS:000892509500082.Journal
Cancer ResearchDOI
10.1158/1538-7445.AM2022-CT562Additional Links
https://dx.doi.org/10.1158/1538-7445.AM2022-CT562Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1158/1538-7445.AM2022-CT562